Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aussie trading
My observations (probably incorrect)
Trading in Australia has followed,not led,US
trading Australia except for the day after the
CR. If I’m corrected we should see a nice pop down
under tonight
The stock formed a bullish hammer
candlestick patten today. If the stock opens
higher tomorrow the buyers will take charge.
Mike
I have some questions also
What is your time frame regarding “many” months to get back to
9. I expect a base will be built until the next catalyst. The next
Report is about 2 and a half months away.
Can this really be called a dump at this point.
So far, the price has has traded right around the Offering price.
If it stays in this range is it a dump or merely an adjustment
to the capital raise?
If the CEO is smart, why did he wait to sell at the offering
price, when surely he knew of the ASX uplisting and
the impending capital raise in advance? Might it be he
Sold a portion of a stock grant or option exercise to
offset the 47% tax liability before year end. Regardless
of price the same percentage of shares would have to be sold.
I do realize it is approved for one
Indication at the present time and well
along in the pediatric trials. To broaden
the market will require additional
trials and product launches are expensive
and take some time to get customers to adopt
A new product. I’m am not in any sway
negative on the system. In fact, quite the
opposite. I just point out that doubling or tripling
In price takes time and over expectations often
lead to disappointment.
A NASDAQ listing would open the stock up to
many funds that are not permitted to invest in
stocks that don’t meet certain criteria
I believe the future ReCell is bright but there
Are always bumps in the road and delays
Along the way
I love the enthusiasm on this
board for Avita, but I would caution that
As good as the product is, the wheels move
slowly at the FDA and the process is
expensive. If the product does what the papers
presented at the burn conference say it does,
and I have little doubt it does, then the stock
price will rise over time.
In my opinion, pushing for NASDAQ
compliance and listing would do more in
the short term than a publicity campaign.
Thank you for your cogent thoughts on
the question of GBLX valuation and how you
would transform the management team to
improve operations.
I appreciate the penny stock investment advice
But I have already retained gblxfan to handle
all of my finances, due to his far superior
knowledge and demeanor.
Just sayin’
Believe me, you are totally incapable of hurting
my feelings. Obtuse? Irresponsible? Neophyte?
And now references to Alzheimer’s and hypertension
These were not my words. It appears that if one disagrees
With your opinions they are wearing blinders.
Only Shaark knows the truth about GBLX and
those who have a different point of view are
subject to ad hominem attacks.
Your arguments only center on the fact that you
believe that management is incompetence and
dishonest.
I ask these questions :
With whom would you replace existing management
and what could the do to move the share price
that is not being done?
What would a shareholder lawsuit or an SEC
investigation accomplish?
Is the any value in their franchises, collaborations
patents, and if so, how do they compare of other
Penny cannabis stocks?
Do you consider GBLX merely another purveyor of
weed or a aspiring biotech trying to differentiate
their product from other growers?
Is there any value in being able to cultivate strains
that are sterile and do not experience drift from one
grow cycle to the next?
Are there opportunities in hemp cultivation?
So far, I am an irresponsible, obtuse
neophyte ostrich. A 72 year old neophyte,
I might add who bought his first stock in
1970.
You say,”play it as you see it” yet respond
Negatively to every person who posts an
opinion that differs from yours. It’s very
altruistic of you to try to save all these people
from themselves.
The risks have been laid out in the K’s for
years. It didn’t go your way. Move on or
buy yourself a pacifier and stop whining
Ostrich here!!!
I would like you to read my
post #4698 in which I explained
my thoughts on GBLX, over a
year ago. At the end, I say that
the price could go to zero.
Then please read the reply from
Shaark (post #4700), who states
That I am irresponsible and obtuse
for even suggesting such a
possibility.
I’m way down and I knew the risk
when I got in. You’re way down
and crying and trying to blame
someone else for your decision.
Drop line
How dare you post anything on
This board that makes sense or expresses
an opinion that may be positive. Don’t you
realize this is a place for preadolescents to
make bathroom jokes and cry babies who can’t
take responsibility for their investments decisions
and therefore blame management for everything.
How am I wrong when you just reiterated my point. FDA
can’t move until scheduling is changed and more
sources are approved to supply researchers. Read
the pending legislation.
State level is fine to proceed, but FDA is
Restricted until laws change.
Minor cannabinoids and terpines are not THC and
CBD. I am very optimistic about the future of
GBLX but realistically the short to medium term
Is dependent upon what they can do in the states
Where they currently do business. FDA process is
Long and costly and even Poss says they can’t do it on
their own. Good revenues will move the share
price higher until they can show proof of concept on the federal level
and find a partner with deep pockets. I’m not being
negative and don’t see the sky falling, merely
realistic based on the state of the sector as it
stands today.
Only if they use the plants from Mississippi. The are the only ones approved to supply any company in the US.
My perspective FWIW
This is the only decision the FDA could make
under current law. There is legislation pending
that will change that quickly, but not overnight.
That part of the company as Poss termed it would
be the rocket ship.
Their addressable market right now is Nevada, with
Louisiana soon to come. There is a 10k due by
June 29, unless they ask for a delay, and that
will tell a lot. Strong sales would be a catalyst and
last year was minimal. From there add in La. so
The next year looks positive. They have a lot going on
that needs to be funded, so if they performed we
will be rewarded.
I emailed the company about this and was told they
still hold a non-controlling interest in AISO. By my calculations
from the 10k it works out to 49% unless
further transactions have been made
since the 10k was issued, which in possible
Thanks so much. Very informative and helpful
I’d be interested to find out the status of the deal.
The 10k says it was 66-34% joint ownership, then as you pointed out
GB transferred 17%. That would leave 49%. It also
states in the press release that AISCO is operating
under a exclusive license granted to them by
GB Sciences. Since you visited the facility, you
probably known better than I. I know these units
are modular and can be expanded to any size
desired. Are they still being used Nevada to
grow plants or are they now using a different
method now? I certainly hope you’re correct as to
the timing of achieving break-even. The reason I
questioned the timing is that they have so many
Irons in the fire right now that SG and A expenses have to be
rising. If Nevada can cover that it would be great.
Thank you for your input
Thanks. I missed the 17% transfer reducing GB’s
stake. Still appears to be an income producing
opportunity in the future. IMO
I agree with most of your points, but I think your
Timeline could be a little ambitious as to cash flow
positive and preclinical trials. Here’s my take for
what it’s worth.
1. I love the recreational market in Vegas. It might
slow future dilution
2. The FDA advisory panel unanimously recommended
approval of GW pharma’s CBD derived drug. In
order to approve the drug, the FDA has to
reschedule Cannabis out of schedule 1 or it can’t be posed.
3. There are bills in the Senate and House that
will force the Justice Department. One part is to
make it very much easier for Universities to due
plant research with fewer barriers. LSU?
4. A few days back there were a few posts
about Growblox-AISCO that were pretty much
ignored. The 10k details the deal that granted rights
The current Puerto Rico operator. GBLX still owns over
60% of the company. The box will grow about 100
pounds on consistent quality and profile product a year.
Not great for the big grower, but ideal
for the researcher who is not dealing in quantity
But wants quality that’s plug and play.
5. There’s an awful lot of money waiting to invest
in the sector but can’t, not the least of which
belongs to Pharma and biotech. I can’t find a lot
of companies that do what GB does. Grow your
own
5. The tissue propagation process they use to
obtain consistency is mostly overlooked, but
could produce significant licensing revenue.
They did an 8K when they announced their
intention to purchase. I don’t believe they have to do another
One until the deal is closed, which could take a little time
I don’t know if anyone saw the Weed 4
broadcast on CNN last night. They showed
Shango dispensary, which is Nevada Pure’s
operation in Las Vegas Nevada
If more conditions are eligible, more patients will
be able to use the products, thus increasing sales.
During the January MJ stock mania, I think the company probably got overvalued in the run-up pre- Sessions. The market over reacted both to the upside and downside. Since then, the company has started unlocking some of its intrinsic value based on a series of deals and collaborations and it has gone largely unnoticed. With all of the positive industry news that has come to light in the last week, I believe there will be more interest in the sector as an investment or trade. Management has been able to differentiate itself from the vast majority of other cannabis and cannabis related companies based on a strong science based foundation. As things like FDA de scheduling and access to the banking system become reality and barriers to investing are removed, I can see this stock at levels that will make today’s price a distant dream. Hopefully, today’s is the beginning of a sustained move upward.
GBLX fan
No offense, but I can believe it. Instead of coming to this board to look for information or another’s opinion on the company you displayed some pretty childish behavior based on some perceived slight. Rather than hurling insults, you might have used a piece or two of information posted here to initiate some due diligence on the company. Right now, it looks like you made a not so good decision. Time will tell. In the mean time, learn from it. I bear you no ill will and wish you good fortune, but your recent behavior leaves much to be desired
You’re welcome, friend. Looking forward to you update on the company
NevadaPure opened in 2015 to provide medical marijuana. In September 2016 they partnered with Shango about 2 months before the vote to legalize recreational. At that point Shango took over the operation and the name changed. Shango is out of Portland and was just entering Nevada. Apparently, the partnership didn’t work out and NevadaPURE sold out
A company called Nevada pure they have cultivation license and a dispensary. They currently have about &16 million in sales. Sorry about the link
-McConnell backs bill to ease up on hemp cultivation - POLITICOtext-here[/tag]
I think if you’ve already voted then you’re all set. They will be soliciting proxies from those who didn’t bother to vote.
Sorry. Bad link. Google 1099 employee
https://www.strictlybusinesslawblog.com/2011/08/04/there-is-no-such-thing-as-a-1099-employee/p
I hope the link works. The IRS has specific rules regarding independent contractors and penalties and back taxes apply if the rules are violated. I don’t understand th point of attempting to do this. It’s not like cash from operations just sits there and can’t be used because of the banking rules. If they chose to pay people in cash they could do that regardless of whether the get a 10999 or a W2 at the end of the year.
Looks like they didn’t have enough proxies for a quorum, so the meeting has been continued until April 6. Too many non voters.
I was struck by the size of the royalty listed in the 8k you posted earlier. It struck me as a good deal for the company, but I had no idea of what that meant in dollar terms. Thanks for the information
Two nice green days in a row. There has been good size on the bid to absorb the overhang of sellers at around 0.70. Now that the up and down frenzy seems to have settled down, I’m hoping for a nice steady move up into the 0.8-0.9 range.
I believe they received 15% of shares in GB Sciences Louisiana LLC which is a wholly owned subsidiary of the parent company GB Sciences. Parent company’s shares would be unaffected.
Based on their concept and business plan, further dilution is inevitable for the foreseeable future. They are not content to merely be a nice little grow and dispense operation. Their aim is to be a medical or biotech company You are buying a concept based on scientific evidence more than an operating company the it generating free cash flow at this point.
The LSU deal comes with commitments and obligations that require periodic payments to the university. Many in Louisiana were very much against the choice of GBLX based on their financial position and the “going concern “ statement in their 10q or 10k. LSU saw something in their science that led them to make that choice. In my opinion, that validates their scientific approach. Wellcana is a recently formed LLC of local investors who bought in. This will provide capital to complete and maintain the facility and meet obligations until they can generate sales in the state.
They have a lot going on in many areas that have the potential to create meaningful revenue and cash flow, but they’re not the yet. Meanwhile, they have few options to raise money except to issue stock.
They are buying at 15% stake in GBSL which is the Louisiana venture and not the entire company. That would put a value of 20 million dollar value on the Louisiana deal as it stands today.
I think earnings report is due tomorrow. Can anyone confirm that?
Shaark
I you read the latest financial report there is a “going concern” warning placed their By the accounting firm that audits their financials. I did not say probability but it if their auditors are cautious enough to put it there,it would be irresponsible of my not to point out the risk of the company going out of business.